Olaparib

Wilms Tumor

National Cancer Institute (NCI)Small moleculePhase 2Active

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 89/ 100

Competitive context

39 Active assets in the Wilms Tumor cohort.

Asset / Sponsor	Phase	Rating
DOXORUBICIN Children's National Research Institute	Phase 2	BB
(+)-VINCRISTINE Centre Oscar Lambret	Phase 2	BB
Itraconazole Samsung Medical Center	Phase 4	BB
Irinotecan Centre Oscar Lambret	Phase 2	BB
Cyclophosphamide St. Jude Children's Research Hospital	Phase 2	BB

View all 50 →

Same molecule, other indications

Olaparib is also rated in:

breast carcinomaActive

BBB

Indicative · Phase 4

73 / 100

fallopian tube serous adenocarcinomaActive

BBB

Indicative · Phase 3

72 / 100

ovarian carcinomaActive

BB

Indicative · Phase 4

71 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.